<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00314743</url>
  </required_header>
  <id_info>
    <org_study_id>03-1192</org_study_id>
    <nct_id>NCT00314743</nct_id>
    <nct_alias>NCT00285272</nct_alias>
  </id_info>
  <brief_title>Efficacy &amp; Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron &amp; Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation</brief_title>
  <official_title>A Study Evaluating the Efficacy and Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of aprepitant in preventing acute and
      delayed chemotherapy induced nausea and vomiting when administered in combination with
      intravenous or oral ondansetron and intravenous or oral dexamethasone in the autologous
      transplant setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the efficacy of aprepitant in preventing acute &amp; delayed chemotherapy induced nausea &amp; vomiting when administered in combination with intravenous or oral ondansetron &amp; intravenous or oral dexamethasone in the autologous transplant setting.</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the the severity, frequency, and duration of chemotherapy induced nausea and vomiting in patients receiving aprepitant and compare these results to a control group, not receiving aprepitant.</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the need for breakthrough antiemetics in patients receiving aprepitant and compare these results to the control group</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the incidence of complications associated with chemotherapy induced nausea and vomiting in patients receiving aprepitant and compare these results to the control group.</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety of aprepitant in combination with ondansetron and dexamethasone in the autologous transplant setting.</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Control (No aprepitant)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regimen #1 (BEAM; NHL and HL)
Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)
Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 20 mg IV)
Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)
Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)
Regimen #2 (MM and Amyloidosis)
Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 20 mg IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental (with aprepitant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant 125 mg PO will be given 30 minutes prior to the first dose of chemotherapy followed by Aprepitant 80 mg PO QD for the remainder of chemotherapy and continuing for a total of 2 days after completing the regimen.
Regimen #1 (BEAM; NHL and HL)
Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)
Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 10 mg IV)
Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)
Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)
Regimen #2 (MM and Amyloidosis)
Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 10 mg IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <arm_group_label>Control (No aprepitant)</arm_group_label>
    <arm_group_label>Experimental (with aprepitant)</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Control (No aprepitant)</arm_group_label>
    <arm_group_label>Experimental (with aprepitant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <arm_group_label>Experimental (with aprepitant)</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients 18 years of age or older

          -  Patients deemed eligible to undergo autologous bone marrow or peripheral stem cell
             transplant therapy per usual transplant inclusion and exclusion criteria

          -  Patients with Non-Hodgkins Lymphoma, Hodgkins Lymphoma or Multiple Myeloma or
             Amyloidosis

          -  Written informed consent

        Exclusion Criteria:

          -  Nausea at baseline

          -  Chronic use of other antiemetic agent(s)

          -  Gastrointestinal obstruction or active peptic ulcer

          -  Radiation therapy to pelvis or abdomen within 1 week before or after study day 1

          -  Allogeneic stem cell transplant recipient

          -  Aspartate transaminase (AST) &gt; 3x upper limit of normal (ULN)

          -  Alanine transaminase (ALT) &gt; 3x ULN

          -  Bilirubin &gt; 3x ULN

          -  Alkaline phosphatase &gt; 3x ULN

          -  Creatinine &gt; 2

          -  Documented hypersensitivity to any component of study regimen

          -  Pregnant or lactating women

          -  Participating in a clinical trial which involves other investigational agent(s)

          -  Patients taking any of the following medications at time of study day 1: warfarin,
             oral contraceptives (except for the administration of stopping menses), tolbutamide,
             phenytoin, midazolam, ketoconazole, rifampin, paroxetine, and/or diltiazem.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F DiPersio, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2006</study_first_submitted>
  <study_first_submitted_qc>April 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2006</study_first_posted>
  <last_update_submitted>May 22, 2013</last_update_submitted>
  <last_update_submitted_qc>May 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients with Non-Hodgkins Lymphoma or Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Neurokinin A</mesh_term>
    <mesh_term>Substance P</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

